

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)



(10) International Publication Number
WO 2024/031155 A1

(51) International Patent Classification:

C07K 7/02 (2006.01) A61K 51/04 (2006.01)
A61K 9/00 (2006.01) A61P 35/00 (2006.01)
A61K 33/241 (2019.01)

(21) International Application Number:

PCT/AU2023/050763

(22) International Filing Date:

11 August 2023 (11.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2022902273 11 August 2022 (11.08.2022) AU
2022902274 11 August 2022 (11.08.2022) AU

(71) Applicant: **ADVANCELL ISOTOPES PTY LIMITED**
[AU/AU]; Level 7, 167 Macquarie Street, Sydney, New
South Wales 2000 (AU).

(72) Inventors: **PUTTICK, Simon**; c/- AdvanCell Isotopes Pty
Limited, Level 7, 167 Macquarie Street, Sydney, New South
Wales 2000 (AU). **TIEU, William**; c/- AdvanCell Isotopes
Pty Limited, Level 7, 167 Macquarie Street, Sydney, New
South Wales 2000 (AU). **KUAN, Kevin**; c/- AdvanCell Iso-
topes Pty Limited, Level 7, 167 Macquarie Street, Sydney,
New South Wales 2000 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins Street,
Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: **RADIOPHARMACEUTICALS**




FIGURE 1A

(57) Abstract: This application relates generally to prostate specific membrane antigen (PSMA) targeting radiopharmaceutical compounds, and their uses in nuclear medicine for the in-vivo imaging of various tissues, and the treatment and/or prevention of various PSMA-expressing cancers, especially prostate cancer.

WO 2024/031155 A1